Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.

Wenxian Wang,Mingxiang Ye,Fei Pang,Qing Wei,Qian Wang,Ziming Li,Chuangzhou Rao,Xiao Hu,Zhuan Hong,Guansong Wang,Yuanli Xia,Lu Si,Nong Yang,Jing Cai,Qian Chu,Zhengbo Song,Zhansheng Jiang,Liyun Miao,Shenglin Ma,Jingping Yuan,Wen Li,Jiexia Zhang,Xingxiang Pu,Donglai Lv,Xuefei Shi,Fen Lan,Junping Zhang,Feng Wang,Hui Guo,Bin Lian,Gen Lin,Yuanzhi Lu,Xiuyu Cai,Xinqing Lin,Anwen Liu,Lingfeng Min,Kai Wang,Yong Song,Huafei Chen,Wei Hong,Lin Wu,Rui Meng,Chuanhao Tang,Tangfeng Lv,Ping Zhan,Jianya Zhou,Xiaoyan Li,Huijing Feng,Shirong Zhang,Yiping Zhang,Bing Wan,Shuitu Feng,Wenfeng Fang,Wenbin Gao,Yongchang Zhang,Rui Zhang,Genhua Yu,Jing Kang,Wang Yao,Jingxun Wu,Lin Shi,Dongqing Lv,Zanmei Xu,Hongbing Liu,Dong Wang,Yinbin Zhang,Chengzhi Zhou,Congying Xie,Lin Wang,Yanru Xie,Liping Wang,Yu Chen,Jian Huang ,Caoyang Yu ,Zhen Yu ,You‐Cai Zhu ,Xiao Liang ,C Xu ,Ping‐Li Sun ,M Fang

doi:10.1111/1759-7714.14693

Abstract

Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.

Full Text